Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 289 of 6351
-
Can a cancer drug reboot the immune system in chronic fatigue syndrome?
Disease control Not yet recruitingPost-acute infection syndromes (PAIS) are long-lasting health problems that can develop after an infection. They include post-COVID-19 syndrome and similar illnesses following other infections. Some people with PAIS develop myalgic encephalomyelitis/chronic fatigue syndrome (ME/C…
Phase 2 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a simple device help curb malaria in children?
Prevention Not yet recruitingThis study will evaluate the implementation of integrating Guardian spatial emanators into the existing AVENIR II azithromycin mass drug administration program in Niger. The objective is to assess whether Guardian can be feasibly, acceptably, and effectively delivered through the…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jul 24, 2026 00:00 UTC
-
A gentle current to the brain: a new hope for stroke arm recovery?
Disease control Not yet recruitingThis study tests whether a brain stimulation technique called tACS can help stroke patients recover movement in their affected arm. Patients receive either real or fake brain stimulation three times a week for about a month (12 sessions total). During each session, they wear a c…
Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Old drug, new hope: mercaptopurine tested against rare cancer syndrome
Disease control Not yet recruitingThis phase I/II trial studies the side effects and best dose of mercaptopurine, and to see how well it works in treating patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is a rare inherited disorder that increases the risk of developing benign (not …
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Major trial pits drugs vs. surgery vs. stents for failing hearts
Disease control PausedThe ISCHEMIA-HF trial will randomize participants with multivessel coronary artery disease (CAD) with ejection fraction (EF) ≤40% in a 1:2:2 fashion to guideline-directed medical therapy (GDMT):coronary artery bypass grafting (CABG):percutaneous coronary intervention (PCI).
Phase 3 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Ancient herbal blend may get bowels moving after surgery
Disease control Not yet recruitingThis Phase 2, multicenter, randomized, double-blind, placebo-controlled master protocol study will evaluate the safety and efficacy of TU-100, adjunctive to an Enhanced Recovery After Surgery (ERAS) pathway, for accelerating gastrointestinal recovery following major abdominopelvi…
Phase 2 • Sponsor: Tsumura USA • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a tailored therapy curb drug use after prison?
Disease control Not yet recruitingThis study aims to improve health outcomes for people who use drugs after release from incarceration, a period of high risk for overdose and other adverse outcomes. It will examine an individually tailored behavioral activation (IT-BA) intervention integrated into a reentry prima…
Sponsor: Catherine E. Paquette, PhD • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
One or two infusions could replace weeks of antibiotics for heart infection
Disease control Not yet recruitingThis study compares two treatment strategies for antibiotic therapy in endocarditis. The aim of the study is to determine which treatment is more effective overall and better tolerated by patients. The first strategy is standard therapy: treatment with proven antibiotics, which …
Phase 3 • Sponsor: Stefan Hagel • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Virtual obstacles, real gains: AI and AR join forces to steady aging steps
Prevention Not yet recruitingFalls are a common problem in adults within the age of 55-80 years and can lead to injury and loss of independence. This study is testing a new type of balance training using augmented reality (AR). In this intervention, participants will see virtual objects, such as obstacles, p…
Sponsor: McMaster University • Aim: Prevention
Last updated Aug 27, 2026 00:00 UTC
-
New drug cocktail aims to tame tough leukemias
Disease control Not yet recruitingThe goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML. The goal of Phase 2 is to learn if asciminib in combination with FLAG-Ida and venetoclax can help to control the disease.
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Virus and radiation combo takes on childhood brain cancer
Disease control Not yet recruitingThe goal of this clinical research study is to learn about the safety and effects of G207 combined with radiation therapy in patients with recurrent or progressive high-grade glioma (HGG).
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
Disease control Not yet recruitingThis study investigated the efficacy and safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer.
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can a vaccine plus immune booster tackle resistant prostate cancer?
Disease control Not yet recruitingThis phase Ib single-center open-label de-escalation study uses a modified 3+3 design to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination of standard of care Sip-T and N-803 in patients with metastatic androgen pathway modulation resista…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Radiation-Free brain imaging for kids? ultrasound may offer a safer path
Diagnosis Not yet recruitingAcute brain injury (ABI) is a leading cause of death and long-term disability in children. Diagnosis depends on fast neuroimaging, and head computed tomography (CT) is the bedside reference standard despite exposing the developing brain to ionizing radiation. A safe, portable, ra…
Sponsor: Virginia Commonwealth University • Aim: Diagnosis
Last updated Aug 21, 2026 00:00 UTC
-
New drug cocktail aims to wipe out Hard-to-Treat leukemia and MDS
Disease control Not yet recruitingThis phase II MyeloMATCH treatment substudy tests the addition of olutasidenib to usual treatment in patients with higher-risk myelodysplastic syndrome (MDS) or patients with acute myeloid leukemia (AML) with a mutation in the IDH1 gene. Olutasidenib blocks the protein made by th…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Experimental combo targets genetic weakness in aggressive blood cancers
Disease control Not yet recruitingTo find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations. To learn if the recommended dose of ropeinterferon alfa-2b found in Dose Escalation in combination with azacitidine can help to co…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a new injection tame relapsing MS?
Disease control Not yet recruitingThe purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS).
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could stem cells ease Parkinson's symptoms? new trial launches
Disease control Not yet recruitingThis clinical trial investigates the safety and therapeutic potential of mesenchymal stem cell-based therapies in patients with parkinsonism. The study evaluates neuroinduced mesenchymal stem cells and mesenchymal stem cell-derived exosomes as potential regenerative treatments t…
Phase 2 • Sponsor: Biocells Medical • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a daily pill tame rare cancers in teens? new trial investigates
Disease control Not yet recruitingResearchers are looking for new ways to treat adolescents with locally advanced, unresectable, or metastatic solid tumors. Participants were enrolled into pheochromocytoma/paraganglioma (PPGL), wild type gastrointestinal stromal tumor (wtGIST), and Von Hippel-Lindau (VHL) disease…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for older AML patients: targeted radiation combo enters human testing
Disease control PausedThis phase I trial tests the safety, side effects, and best dose of lintuzumab-Ac225 in combination with venetoclax and ASTX-727, and how well they work in treating patients with newly diagnosed acute myeloid leukemia (AML). Lintuzumab-Ac225 is a monoclonal antibody, called lintu…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC